Interstitial cystitis and bladder pain syndrome are essentially interchangeable as there is no accepted definition that clearly delineates the interstitial cystitis syndrome from bladder pain syndrome. IC/BPS is generally agreed to be defined as chronic pelvic pain, pressure, or discomfort perceived to be related to the urinary bladder when accompanied by at least one other urinary symptom such as persistent urge to void or urinary frequency when in the absence of confusable diseases. The Consultation believes that patients who meet the definition and have a Hunner lesion should be considered to have a distinct confusable disease (Hunner lesion disease — HLD) and be managed accordingly. It follows that early cystoscopy is essential in establishing whether the diagnosis is HLD or IC/BPS. As no single treatment works well over time for a majority of patients, the treatment approach should be tailored to the specific symptoms of each patient and a multidisciplinary approach may be required. A reasonable diagnostic and treatment algorithm is offered by the Consultation. For methodology and the complete report of the committee with complete references, please refer to the 7th edition of the International Consultation on Urological Diseases Incontinence.

The Hippo pathway regulates and contributes to several hallmarks of prostate cancer (PCa). Although the elucidation of YAP function in PCa is in its infancy, emerging studies have shed light on the role of aberrant Hippo pathway signaling in PCa development and progression. YAP overexpression and nuclear localization has been linked to poor prognosis and resistance to treatment, highlighting a therapeutic potential that may suggest innovative strategies to treat cancer. This review aimed to summarize available data on the biological function of the dysregulated Hippo pathway in PCa and identify knowledge gaps that need to be addressed for optimizing the development of YAP-targeted treatment strategies in patients likely to benefit.

An emerging theory regarding the potentially autoimmune nature of painful bladder syndrome/interstitial cystitis (PBS/IC) had led to several studies being conducted to assess the possible therapeutic effect of immunotherapeutic options for PBS/IC. This review presents the available evidence regarding the potential autoimmunity-based pathogenesis of PBS/IC and focuses on a main representative of the immunotherapeutic modalities for PBS/IC, aiming to summarize, evaluate, and present available data regarding the potential therapeutic role of monoclonal antibodies for PBS/IC patients. A non-systematic narrative and interpretative literature review was performed. The monoclonal antibodies included in the review were the anti-tumor necrosis factor-alpha (anti-TNF-alpha) agents adalimumab, which showed no difference compared to placebo, and certolizumab pegol, which showed statistically important differences in all outcome measures compared to placebo at the 18-week follow-up visit. Anti-nerve growth factor (anti-NGF) agents were also reviewed, including tanezumab, which showed both positive and negative efficacy results compared to placebo, and fulranumab, the study of which was discontinued owing to adverse events. In summary, monoclonal antibody therapy remains to be further researched in order for it to be proposed as a promising future treatment option for PBS/IC.